Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2023)

Innate Pharma (IPHA) has disclosed Non-Current Deferred Tax Liability for 6 consecutive years, with $9.7 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non-Current Deferred Tax Liability rose 10.85% year-over-year to $9.7 million, compared with a TTM value of $9.7 million through Dec 2023, up 10.85%, and an annual FY2023 reading of $9.7 million, up 11.45% over the prior year.
  • Non-Current Deferred Tax Liability was $9.7 million for Q4 2023 at Innate Pharma, up from $8.7 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $9.7 million in Q4 2023 and bottomed at $1.4 million in Q4 2019.
  • Average Non-Current Deferred Tax Liability over 5 years is $6.8 million, with a median of $8.4 million recorded in 2020.
  • The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 493.61% in 2020, then crashed 31.93% in 2021.
  • Year by year, Non-Current Deferred Tax Liability stood at $1.4 million in 2019, then surged by 493.61% to $8.4 million in 2020, then tumbled by 31.93% to $5.8 million in 2021, then skyrocketed by 51.98% to $8.7 million in 2022, then rose by 10.85% to $9.7 million in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for IPHA at $9.7 million in Q4 2023, $8.7 million in Q4 2022, and $5.8 million in Q4 2021.